ProShare Advisors LLC Makes New $244,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

ProShare Advisors LLC purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 7,220 shares of the company's stock, valued at approximately $244,000.

Several other large investors have also modified their holdings of TEM. Operose Advisors LLC bought a new stake in Tempus AI during the fourth quarter valued at about $25,000. Farther Finance Advisors LLC purchased a new stake in shares of Tempus AI during the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC boosted its position in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after purchasing an additional 965 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Tempus AI during the 4th quarter worth $49,000. Finally, First Horizon Advisors Inc. increased its position in Tempus AI by 207.9% during the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock valued at $55,000 after buying an additional 1,108 shares in the last quarter. Institutional investors own 24.22% of the company's stock.

Tempus AI Stock Performance

Shares of NASDAQ TEM traded up $1.39 during midday trading on Wednesday, reaching $63.35. 5,242,319 shares of the stock were exchanged, compared to its average volume of 6,800,324. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm has a market cap of $10.97 billion and a price-to-earnings ratio of -8.17. The firm has a 50-day simple moving average of $52.48 and a two-hundred day simple moving average of $51.90. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.03. The firm had revenue of $255.74 million for the quarter, compared to analysts' expectations of $248.13 million. Tempus AI's revenue was up 75.4% compared to the same quarter last year. As a group, analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEM has been the subject of several recent analyst reports. Guggenheim reissued a "buy" rating on shares of Tempus AI in a report on Tuesday, February 25th. BTIG Research began coverage on shares of Tempus AI in a research note on Monday, April 21st. They issued a "buy" rating and a $60.00 target price for the company. Needham & Company LLC reissued a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research report on Wednesday, May 7th. TD Cowen reaffirmed a "buy" rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Piper Sandler boosted their price objective on shares of Tempus AI from $55.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, May 15th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Tempus AI has an average rating of "Moderate Buy" and a consensus price target of $63.42.

Insider Activity at Tempus AI

In other news, Director David R. Epstein sold 990 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $46.83, for a total transaction of $46,361.70. Following the completion of the sale, the director now owns 26,284 shares of the company's stock, valued at $1,230,879.72. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Wayne A.I. Frederick sold 3,000 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $45.54, for a total value of $136,620.00. Following the sale, the director now owns 26,514 shares of the company's stock, valued at approximately $1,207,447.56. This trade represents a 10.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 139,888 shares of company stock worth $7,938,111 in the last 90 days. Corporate insiders own 27.60% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.